Item 8.01. Other Events.

On August 25, 2020, Morphic Holding, Inc. ("Morphic") announced that AbbVie Inc. ("AbbVie") has exercised its license option under the companies' existing research and development collaboration agreement (the "AbbVie Agreement") to develop Morphic's ?v?6integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis and additional indications. The license covers ?v?6 integrin-specific inhibitors discovered from Morphic's proprietary MInT Platform, including the compounds MORF-720 and MORF-627. Pursuant to the AbbVie Agreement between Morphic and AbbVie, Morphic will receive a license fee of $20.0 million, with potential future development milestone payments and royalties from the sales of any commercialized candidates.





Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding Morphic or AbbVie's plans to develop and commercialize oral small-molecule integrin therapeutics, the ability of MORF-720, MORF-627 or another ?v?6 integrin inhibitor to treat idiopathic pulmonary fibrosis or any other fibrotic disease, the potential payments and royalties under the AbbVie Agreement, or our expectations regarding our collaboration with AbbVie. Such risks and uncertainties include, among others, the risks identified in Morphic's filings with the Securities and Exchange Commission ("SEC"), including its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2020, filed with the SEC on August 10, 2020, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Morphic's results of operations, which would, in turn, have a significant and adverse impact on Morphic's stock price. Morphic cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Morphic undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

© Edgar Online, source Glimpses